First human tests begin for new vaginal infection treatment
NCT ID NCT07302035
Summary
This early-stage study aims to test the safety and measure how the body processes a new vaginal treatment called GenSci142 for bacterial vaginosis. The trial will enroll 30 healthy Chinese women who will receive either the experimental treatment or a placebo. Researchers will monitor side effects and track how the drug moves through the body to determine safe dosage levels for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL VAGINOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.